MOLECULAR PARTNERS ADS/1 (F:6ML0) — Market Cap & Net Worth
Market Cap & Net Worth: MOLECULAR PARTNERS ADS/1 (6ML0)
MOLECULAR PARTNERS ADS/1 (F:6ML0) has a market capitalization of $133.19 Million (€113.92 Million) as of May 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #18087 globally and #1691 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MOLECULAR PARTNERS ADS/1's stock price €3.54 by its total outstanding shares 37411668 (37.41 Million). Analyse MOLECULAR PARTNERS ADS/1 cash conversion from operations to see how efficiently the company converts income to cash.
MOLECULAR PARTNERS ADS/1 Market Cap History: 2021 to 2026
MOLECULAR PARTNERS ADS/1's market capitalization history from 2021 to 2026. Data shows change from $752.30 Million to $155.71 Million (-26.36% CAGR).
MOLECULAR PARTNERS ADS/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MOLECULAR PARTNERS ADS/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
43.83x
MOLECULAR PARTNERS ADS/1's market cap is 43.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $752.30 Million | $9.33 Million | -$63.78 Million | 80.63x | N/A |
| 2022 | $242.75 Million | $189.56 Million | $117.85 Million | 1.28x | 2.06x |
| 2023 | $165.33 Million | $7.04 Million | -$61.98 Million | 23.49x | N/A |
| 2024 | $217.82 Million | $4.97 Million | -$54.04 Million | 43.83x | N/A |
Competitor Companies of 6ML0 by Market Capitalization
Companies near MOLECULAR PARTNERS ADS/1 in the global market cap rankings as of May 3, 2026.
Key companies related to MOLECULAR PARTNERS ADS/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
MOLECULAR PARTNERS ADS/1 Historical Marketcap From 2021 to 2026
Between 2021 and today, MOLECULAR PARTNERS ADS/1's market cap moved from $752.30 Million to $ 155.71 Million, with a yearly change of -26.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €155.71 Million | -3.78% |
| 2025 | €161.83 Million | -25.70% |
| 2024 | €217.82 Million | +31.75% |
| 2023 | €165.33 Million | -31.89% |
| 2022 | €242.75 Million | -67.73% |
| 2021 | €752.30 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of MOLECULAR PARTNERS ADS/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $133.19 Million USD |
| MoneyControl | $133.19 Million USD |
| MarketWatch | $133.19 Million USD |
| marketcap.company | $133.19 Million USD |
| Reuters | $133.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more